Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY: HAE )

65.95 +0.27 (+0.41%)
Streaming Delayed Price Updated: 12:41 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 177,131
Open 65.37
Bid (Size) 65.85 (2)
Ask (Size) 65.98 (1)
Prev. Close 65.68
Today's Range 65.37 - 67.50
52wk Range 58.80 - 97.97
Shares Outstanding 51,029,618
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How Do Investors Really Feel About Haemonetics?
Via Benzinga
HAEMONETICS CORP/MASS (NYSE:HAE) is probably undervalued for the fundamentals it is displaying.
HAEMONETICS CORP/MASS has caught the attention as a great value stock. NYSE:HAE excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill

Performance

YTD
-15.88%
-15.88%
1 Month
+8.76%
+8.76%
3 Month
-20.87%
-20.87%
6 Month
-8.97%
-8.97%
1 Year
-14.21%
-14.21%

More News

Read More
Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers
Via StockStory
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Pack
Via StockStory
(HAE) - Analyzing Haemonetics's Short Interest
Via Benzinga
Haemonetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Earnings Scheduled For February 6, 2025
Via Benzinga
How Is The Market Feeling About Haemonetics?
Via Benzinga
The Latest Analyst Ratings For Haemonetics
Via Benzinga
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
Via StockStory
Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
For those who appreciate value investing, NYSE:HAE is a compelling option with its solid fundamentals.
Via Chartmill
Haemonetics (NYSE:HAE) Misses Q4 Revenue Estimates
Via StockStory
Earnings To Watch: Haemonetics (HAE) Reports Q4 Results Tomorrow
Via StockStory
Deep Dive Into Haemonetics Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
NYSE:HAE is not too expensive for the growth it is showing.
Via Chartmill
Despite its growth, NYSE:HAE remains within the realm of affordability.
Via Chartmill
While growth is established for NYSE:HAE, the stock's valuation remains reasonable.
Via Chartmill
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
Via Chartmill
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
What Analysts Are Saying About Haemonetics Stock
Via Benzinga
Investors should take note of NYSE:HAE, a growth stock that remains attractively priced.
Via Chartmill
Analyst Expectations For Haemonetics's Future
Via Benzinga
NYSE:HAE stands out as a growth opportunity that won't break the bank.
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.